Molecular Templates Inc (MTEM)

[trop]

nice article (brief excerpt from analyst captured below)

>> 'Sonnier explains, “We believe the potential regulatory path forward with evofosfamide in pancreatic cancer in Japan could transform the company’s valuation and P&L statement. With $33.6 million in cash at the end of the second quarter, we believe the capital should be sufficient to bridge the company to the next material inflection point.”

Furthermore, the analyst understands the biotech firm’s choice to terminate the development on the pipeline drug, asserting, “We agree with management’s decision to discontinue development of tarloxotinib due to the lack of a clear efficacy signal from the Phase II programs.”

In THLD’s favor, Sonnier sees promise as the firm pursues Investigational New Drug-enabling studies with TH-3424, a novel AKR1C3 activated prodrug designed to treat cancer. The drug has already indicated to be considerably upregulated in particular kinds of tumors, including hepatocellular carcinoma.

“Preclinical data supports the ability of TH-3424 to effectively kill cancer cells with upregulated AKR1C3, and we look forward to future updates with the compound,” the analyst concludes." <<


This is an excerpt from article by Julie Lamb, editor dated September 30, 2016, 1:25 PM EDT titled "Analysts Weigh in on Two Collapsing Biotech Stocks: Threshold Pharmaceuticals, Inc. (THLD) and Alcobra Ltd (ADHD)"